DR-468 Investigating effects of cancer treatment on metastatic risk and survivorship
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-468 Investigating effects of cancer treatment on metastatic risk and survivorship
Patients diagnosed with aggressive breast cancers, such as triple-negative breast cancer, often require intensive chemotherapy treatments. While these treatments are …
DR-477 AURORA: Forecasting Treatment Resistance and Evolutionary Trajectories with Multi-Modal Data
AURORA discovers novel biomarkers that predict treatment resistance and guide therapy selection in metastatic cancers. Leveraging Hartwig’s pan-cancer whole-genome sequencing …
DR-434 NECTIN4 Prevalence and Prognostic Value in Metastatic Breast Cancer
NECTIN4 is a protein found on breast cancer cells, and new drugs can target it to kill the cancer. When …
DR-464 Stop-loss in cancer
This project investigates rare genetic changes called stop-loss mutations and their role in cancer. Using mutations called from genome and …
DR-459 Mutational imprints of endogenous DNA damage
DNA carries the instructions to life but is also constantly damaged, causing mutation and disease. Sunlight and cigarette smoke are …
DR-470 RADAR: Repurposing and Analysis of Drugable targets in Atypical Rare cancers
The RADAR study aims to improve outcomes for patients with rare cancers, which affect over 24,000 people annually in the …
DR-310 Clinical actionability for and heritable factors involved in glioblastoma
This project aims to use whole genome sequencing data to 1) describe the driver landscape of glioblastoma, 2) determine potential …
DR-405 Development of a Multi-Omic Test for Cancer of Unknown Primary
Cancer of unknown primary (CUP) is defined as a metastatic cancer where clinical investigations fail to identify the primary tissue …
DR-409 NoCoSMiCC: Non-coding somatic mutations in colorectal cancer
Colorectal cancer (CRC) is a significant malignancy and represents the third most common cancer and second most common cause of …
DR-428 Transcriptomic and Genome-wide machine learning model for predicting immunotherapy benefit in metastatic solid tumors
Immunotherapy has radically changed the treatment landscape across solid tumors. Regardless, biomarkers able to predict immunotherapy benefit are limited, and …
DR-436 Identification of metastatic drivers in breast cancer
Metastasis represents a significant clinical challenge in hormone receptor-positive (HR+) breast cancer. To investigate the genetic drivers of relapse and …
DR-439 Optimization of the Diagnostic and Therapeutic Management of Cancers of Unknown Primary (CUP) Using AI: Integration of Transcriptomic Data to Predict Tumor Origin
Identifying the original tissue of a metastatic cancer is key to choosing the best treatment. Cancers of Unknown Primary (CUP) …
Kanker ontstaat door mutaties in het DNA. Er zijn steeds meer geneesmiddelen die werkzaam zijn bij specifieke fouten in het DNA van de tumor van een individuele patiënt. Een medicijn dat niet past als een sleutel in het slot werkt niet, terwijl je wel het risico van de bijwerkingen hebt.